Look for:

Our offer for

NOVARTIS AG


ISIN:
CH0012005267
WKN:
1200526
- -
Price
-
Difference - (-)

General attributes

ISINCH0012005267
SymbolNOVN
Exchange-
Currency-
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)178,111 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open-
High-
Low-
Close (prev. day)-
VWAP-
Volume (pcs)-
Trading volume-
Number of trades-
Last size-

Futures and Options

Related Futures30
Related Options-

PDF Downloads

Company report: NOVARTIS AGPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



- -
Price
-
Difference - (-)

General attributes

ISINCH0012005267
SymbolNOVN
Exchange-
Currency-
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)178,111 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open-
High-
Low-
Close (prev. day)-
VWAP-
Volume (pcs)-
Trading volume-
Number of trades-
Last size-

Performance and Risk

6m1Y3Y
Perf (%)+21.81%+43.81%+26.34%
Perf (abs.)+14.33+24.38+16.69
Beta0.860.930.79
Volatility17.3817.4216.68
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)80.61 - (13,906)
Ø price 30 days | Ø volume 30 days (pcs.)78.59 - (15,063)
Ø price 100 days | Ø volume 100 days (pcs.)73.88 - (24,517)
Ø price 250 days | Ø volume 250 days (pcs.)68.84 - (18,524)
YTD High | date82.56 - (2019/06/20)
YTD Low | date64.71 - (2019/01/03)
52 Weeks High | date82.56 - (2019/06/20)
52 Weeks Low | date56.35 - (2018/07/02)

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2284&ID_TYPE_IMAGE_LOGO=2

Contact Details

NOVARTIS AG
- -
Lichtstrasse 35 - 4056 Basel
Telefon: +41-61-324-11-11
Fax: +
E-mail: -

PDF Downloads

Company report: NOVARTIS AGPDF Download

Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Members of Management Board

Vasant (Vas) NarasimhanChairman of Managing Board
Klaus MoosmayerMember of Executive Committee
Steffen LangMember of Executive Committee
Aharon GalMember of Executive Committee
Fiona H. MarshallMember of Executive Committee
Harry KirschMember of Executive Committee
Karen HaleMember of Executive Committee
Kees RoksMember of Executive Committee
Lutz HegemannMember of Executive Committee
Michelle WeeseMember of Executive Committee
Patrick HorberMember of Executive Committee
Rob KowalskiMember of Executive Committee
Shreeram AradhyeMember of Executive Committee
Victor BultoMember of Executive Committee

Board of directors

Charles SawyersMember of the administrative board
Nancy AndrewsMember of the administrative board
Simon MoroneyMember of the administrative board
Ana de Pro GonzaloMember of the administrative board
Bridgette HellerMember of the administrative board
Daniel HochstrasserMember of the administrative board
Frans van HoutenMember of the administrative board
John YoungMember of the administrative board
Mary DohertyMember of the administrative board
Patrice BulaMember of the administrative board
Ton BüchnerMember of the administrative board
William WintersMember of the administrative board
Hans Jörg ReinhardtChairman of the administrative boar





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer